News

ASA’s 2026 Grants Push Dermatology Into New Terrain

ASA’s 2026 Grants Push Dermatology Into New Terrain

Thirteen Small Bets With Serious Human Stakes

Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than endlessly circle the same familiar targets.

That matters. ASA says more than 100 million Americans live with skin disorders, roughly one-third of the country. The organization has funded more than $50 million over nearly four decades and supported work by over 300 investigators. Those are meaningful cumulative numbers for a disease-focused nonprofit, though they should not be confused with proof that any particular project will translate into a treatment. Early research is a long, frustrating road. Plenty of sound ideas hit a biological wall.

Still, this cycle looks more deliberate than decorative. The awards span wound healing, cutaneous squamous cell carcinoma, atopic dermatitis, psoriasis, vitiligo, melanoma-related research, systemic mastocytosis, hidradenitis suppurativa and the dermatologic implications of anti-obesity drugs. That is a broad spread, but not a random one. It reflects where patient needs, scientific tools and treatment questions are all colliding.

Corporate Support Is Useful, Not a Verdict

The cleanest financial figure in the announcement is Sun Pharma’s $300,000 contribution backing three Investigative Scientist Awards. Benjamin Nanes at UT Southwestern will study spatial regulation of keratinocyte signaling and transcription in wound healing. Scott Stratman at Mount Sinai is examining inflammatory bowel disease-associated pyoderma gangrenosum, including biomarkers and disease drivers. Carl Gustaf Marten Winge at Stanford is investigating neddylation dependence in cutaneous squamous cell carcinoma.

In plain English, this is the sort of upstream work that can sharpen future drug-development hypotheses, diagnostic approaches or disease models. It is not a revenue event, and anybody dressing it up as one is selling fog. But corporate-supported, independently administered research can be genuinely valuable when it helps define the biology before larger clinical programs start burning through capital.

Good dermatology research does not promise miracles; it reduces the odds of spending years chasing the wrong biology.

ASA’s Medical Advisory Committee, made up of volunteer physicians and scientists, administers the annual process. That governance detail deserves attention. When companies support grants around conditions tied to active therapeutic interest, scientific selection and transparency matter enormously. The notes describe a committee-led process, which is encouraging, but they do not provide individual award amounts, timelines or publication requirements. Those gaps are common in grant announcements, yet they are still the practical details worth watching.

New Research Areas Deserve a Patient Reading

The expansion into hidradenitis suppurativa, systemic mastocytosis and anti-obesity-drug dermatology is the standout feature. Hidradenitis suppurativa is represented by Andrew Sawaya’s project at the University of Miami, focused on epigenetic priming and disease recurrence. That recurrence angle is important: chronic inflammatory diseases do not politely stay solved because a flare settles down.

For systemic mastocytosis, Nicholas Heitman at Mount Sinai will generate a spatially resolved single-cell atlas of the cutaneous mast cell niche. This is highly specialized work, and that is exactly why grants like this belong in the system. Rare or complex diseases can be too small, too messy or too early for broad commercial enthusiasm, even when patients need better answers badly.

Helen He’s Mount Sinai project on tape-strip and blood profiling in people using glucagon-like peptide-1 receptor agonists for obesity may draw the most immediate attention. Anti-obesity medicines have moved fast through medicine and public conversation. Dermatologic effects and patient-specific skin changes deserve rigorous study, not casual anecdotes or internet panic. ASA is not declaring these medicines harmful or beneficial for skin through this award; it is funding an effort to understand the question better. That distinction should remain nailed to the wall.

What I’d Keep an Eye On Next

  • Whether these projects produce published findings that clarify mechanisms, biomarkers or practical treatment gaps.
  • Whether the newer HS, mastocytosis and GLP-1-related research areas receive sustained support beyond a single grant cycle.
  • How findings in skin cancer and inflammatory disease move from laboratory signals toward patient-relevant studies.
  • Whether early-career researchers, including medical student grantee Irene Quan, gain a durable foothold in the field.

The rest of the class reinforces the point that dermatology is not one market or one disease. Nathan Archer’s atopic dermatitis work looks at restoring the lipid barrier to address Staphylococcus aureus colonization. Jesse Veenstra is studying signaling in early cutaneous squamous cell carcinoma. Anna Chrisina Garza-Mayers is examining treatment underutilization in pediatric vitiligo, while Irene Quan’s medical student project addresses clinical fidelity and representational bias in generative AI for vitiligo.

That last project is especially timely. AI systems are already being pushed into clinical-adjacent settings faster than evidence can keep pace. Checking whether they represent vitiligo accurately across patient populations is not glamorous, but it is responsible work.

My read: ASA’s 2026 awards are a sensible portfolio of early scientific bets, not a chest-thumping victory lap. The $300,000 Sun Pharma contribution is notable, and the wider disease scope is welcome. The real scorecard arrives later, in data, replication and better care for patients—not in the announcement itself.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 72

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 51

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 95

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 13

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Boston Scientific Loads Debt Cannon for Penumbra Deal

Updated Category News Views 128

A Very Large Financing Cart Rolled Out Boston Scientific just put an enormous stack of paper into the market, and nobody should mistake this for routine housekeeping. The company priced $3.0 billion of U.S. dollar senior notes and €4.25 billion of euro notes, with proceeds earmarked chiefly for the cash portion of its proposed Penumbra acquisition, alongside cash on...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 0

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Recent Options Trades in Goldman Sachs Group (GS)

Updated Category News Views 230

Bearish Sentiments in Goldman Sachs Group Options Recent activity in the financial market has brought to light the bearish stance among significant investors regarding Goldman Sachs Group (NYSE: GS). While it’s important for retail traders to stay informed, this trend signifies that something noteworthy may be unfolding within the company. Insights from Options...

Continue Reading
Calamos Investments Launches Innovative Bitcoin ETFs with Protection

Updated Category News Views 310

Calamos Investments Introduces Unique Bitcoin ETFs Offering Significant Protection Calamos Investments has recently made headlines with the launch of two groundbreaking exchange-traded funds (ETFs), designed to provide investors with innovative exposure to Bitcoin while maintaining notable downside protection. These new ETFs, namely the CBXJ and CBTJ, offer 90% and 80%...

Continue Reading
Mawson Infrastructure Group Reports Impressive Q3 Financial Gains

Updated Category News Views 192

Mawson Infrastructure Group's Notable Q3 Performance Mawson Infrastructure Group Inc. (NASDAQ: MIGI) is a technology company focused on establishing and managing advanced digital infrastructure platforms. The company recently revealed its financial and operational results, marking the conclusion of the third quarter and the year-to-date for 2025. Financial Highlights from...

Continue Reading
Nékter Juice Bar Teams Up with Krista Horton for New Smoothie

Updated Category News Views 3272

Nékter Juice Bar Launches Exciting Smoothie Collaboration The Krista Kolada Combines Clean Ingredients with Social Power Nékter Juice Bar, a leading name in providing fresh and healthy juice options, has recently rolled out a delightful new offering for its fans. The introduction of the Krista Kolada smoothie marks an exciting collaboration with lifestyle and parenting...

Continue Reading
Kintara Therapeutics Sets Record Date for Exciting CVR Issuance

Updated Category News Views 188

Kintara Therapeutics Announces Record Date for CVR Issuance Kintara Therapeutics, Inc. (NASDAQ: KTRA), a biopharmaceutical company dedicated to developing innovative therapies for solid tumors, recently revealed a record date for the issuance of Contingent Value Rights (CVRs). These rights will be granted to stockholders of Kintara as part of its forthcoming merger with...

Continue Reading